Abbott Posts $2.3B In COVID-19 Test Sales In Q4; Issues FY22 Outlook

Abbott Laboratories ABT has reported Q4 FY21 adjusted EPS of $1.32, down from $1.45 a year ago but better than the consensus of $1.21.

  • Q4 sales of $11.5 billion increased 7.2% on a reported basis and 7.7% on an organic basis, beating the consensus of $10.71 billion.
  • Worldwide sales, excluding COVID-19 testing-related sales, increased 9.6% on a reported basis and 10.3% on an organic basis.
  • Global COVID-19 testing-related sales were $2.3 billion. Abbott has distributed more than 1.4 billion COVID-19 tests since the start of the pandemic.
  • Medical Devices sales increased 15.1% to $3.75 billion on a reported basis and 15.9% organically, driven by continued recovery from the COVID-19 pandemic and strong growth in Diabetes Care.
  • Outlook: Abbott projects FY22 adjusted EPS of at least $4.70, compared to the consensus of $4.78.
  • The company projects Q1 FY22 adjusted EPS of at least $1.50, above the consensus of $1.13.
  • FY22 guidance includes an initial COVID-19 testing-related sales forecast of $2.5 billion.
  • Price Action: ABT shares are down 1.03% at $122.00 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!